ebselen has been researched along with Enterocolitis, Pseudomembranous in 1 studies
ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.
Enterocolitis, Pseudomembranous: An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garland, M | 1 |
| Hryckowian, AJ | 1 |
| Tholen, M | 1 |
| Bender, KO | 1 |
| Van Treuren, WW | 1 |
| Loscher, S | 1 |
| Sonnenburg, JL | 1 |
| Bogyo, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised, Parallel Group, Double Blind, Placebo Controlled, Add on Clinical Trial to Investigate Whether the Lithium Mimetic, Ebselen, Can Reduce Symptoms of Hypomania and Mania in Bipolar Patients[NCT03013400] | Phase 2 | 60 participants (Actual) | Interventional | 2017-10-01 | Completed | ||
| Phase 1b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of SPI-1005 in Meniere's Disease[NCT02603081] | Phase 1/Phase 2 | 40 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus[NCT00762671] | Phase 2/Phase 3 | 60 participants (Actual) | Interventional | 1999-05-31 | Completed | ||
| A Phase 1, Double-blind, Placebo-controled, Randomized Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SPI-1005 (Ebselen)in Healthy Adult Subjects[NCT01452607] | Phase 1 | 32 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for ebselen and Enterocolitis, Pseudomembranous
| Article | Year |
|---|---|
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |
The Clinical Drug Ebselen Attenuates Inflammation and Promotes Microbiome Recovery in Mice after Antibiotic Treatment for CDI.
Topics: Animals; Clostridioides difficile; Clostridium Infections; Cricetinae; Disease Models, Animal; Dysbi | 2020 |